Document Detail

Reduction of myocardial infarct size by SM-197378, a novel Na+/H+ exchange inhibitor, in rabbits.
MedLine Citation:
PMID:  16183058     Owner:  NLM     Status:  MEDLINE    
The effects of SM-197378, 2-[[[amino(imino)methyl]amino]carbonyl]-1-methyl-4-trifluoromethyl-1H-indol-7-yl=hydrogen=sulfate monohydrate, a novel potent Na+/H+exchange inhibitor, on heart injury were studied using a rabbit model involving 30 min of myocardial ischemia and 5 h of reperfusion. Intravenous administration of SM-197378 before ischemia reduced the infarct size by approximately 30-50% in a dose-dependent manner. This anti-necrotic effect was achieved without significant hemodynamic changes. Moreover, administration of SM-197378 before reperfusion also resulted in a significant, approximately 30-40%, reduction in the infarct size. The anti-necrotic effect of pre-ischemic bolus treatment with SM-197378 was compared with that of nicorandil, a K+channel opener with nitrate-like activity, and ischemic preconditioning. With 30 and 60 min of ischemia, the anti-necrotic effects of SM-197378 and ischemic preconditioning were similar and superior to that of nicorandil. With 90 min of ischemia, the anti-necrotic effect of SM-197378 was superior to that of ischemic preconditioning.
Kazuto Yamada; Kazuki Matsui; Shoji Ogawa; Setsuko Yamamoto; Masaya Mori; Masafumi Kitano; Naohito Ohashi
Related Documents :
10844838 - Fentanyl reduces infarction but not stunning via delta-opioid receptors and protein kin...
8044938 - Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a s...
8298068 - Global myocardial ischemia protects the myocardium from subsequent regional ischemia.
8686808 - Physiological and cellular mechanisms of myocardial protection.
369348 - Incidence of new pulmonary perfusion defects after routine cardiac catheterization.
18684258 - A pilot study of a low-tilt biphasic waveform for transvenous cardioversion of atrial f...
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2005-09-23
Journal Detail:
Title:  European journal of pharmacology     Volume:  521     ISSN:  0014-2999     ISO Abbreviation:  Eur. J. Pharmacol.     Publication Date:  2005 Oct 
Date Detail:
Created Date:  2005-10-11     Completed Date:  2006-01-25     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  1254354     Medline TA:  Eur J Pharmacol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  115-23     Citation Subset:  IM    
Sumitomo Pharmaceuticals Co., Ltd., Research Division, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Pressure / drug effects
Dose-Response Relationship, Drug
Heart / drug effects,  physiopathology
Heart Rate / drug effects
Indoles / pharmacology*
Ischemic Preconditioning
Myocardial Infarction / etiology,  pathology,  prevention & control*
Myocardial Ischemia / complications
Myocardial Reperfusion Injury / complications
Myocardium / pathology
Nicorandil / pharmacology
Sodium-Hydrogen Antiporter / antagonists & inhibitors*
Time Factors
Vasodilator Agents / pharmacology
Reg. No./Substance:
0/2-(((amino(imino)methyl)amino)carbonyl)-1-methyl-4-trifluoromethyl-1H-indol-7-yl-hydrogen-sulfate monohydrate; 0/Indoles; 0/Sodium-Hydrogen Antiporter; 0/Vasodilator Agents; 65141-46-0/Nicorandil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of caffeic acid phenethyl ester on gastric acid secretion in vitro.
Next Document:  Tyrosine-phosphorylated Hic-5 inhibits epidermal growth factor-induced lamellipodia formation.